About Monopar Therapeutics Inc.
https://www.monopartx.comMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
CEO
Chandler D. Robinson MBA, MSc
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-13 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
BTIG
Buy
Raymond James
Outperform
Oppenheimer
Outperform
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:1.29M
Value:$87.66M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:659.2K
Value:$44.88M
RA CAPITAL MANAGEMENT, L.P.
Shares:511.21K
Value:$34.81M
Summary
Showing Top 3 of 58
About Monopar Therapeutics Inc.
https://www.monopartx.comMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $4.09M ▲ | $-3.44M ▼ | 0% | $-0.48 ▼ | $-3.44M ▼ |
| Q2-2025 | $0 | $3.23M ▲ | $-2.45M ▲ | 0% | $-0.35 ▲ | $-2.45M ▲ |
| Q1-2025 | $0 | $3.22M ▼ | $-2.62M ▲ | 0% | $-0.38 ▲ | $-3.22M ▲ |
| Q4-2024 | $0 | $11.07M ▲ | $-10.93M ▼ | 0% | $-0.95 ▼ | $-10.93M ▼ |
| Q3-2024 | $0 | $1.57M | $-1.3M | 0% | $-0.11 | $-1.3M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $143.68M ▲ | $144.2M ▲ | $2.64M ▲ | $141.56M ▲ |
| Q2-2025 | $53.25M ▼ | $53.87M ▼ | $1.66M ▲ | $52.2M ▼ |
| Q1-2025 | $54.55M ▼ | $55.09M ▼ | $1.49M ▼ | $53.59M ▼ |
| Q4-2024 | $60.21M ▲ | $60.29M ▲ | $5.25M ▲ | $55.04M ▲ |
| Q3-2024 | $6.02M | $6.07M | $1.12M | $4.95M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.44M ▼ | $-2.09M ▼ | $-2.13M ▼ | $92.39M ▲ | $88.18M ▲ | $-2.09M ▼ |
| Q2-2025 | $-2.45M ▲ | $-1.08M ▲ | $1.19M ▲ | $-316.85K ▼ | $-209.47K ▲ | $-1.08M ▲ |
| Q1-2025 | $-2.62M ▲ | $-5.66M ▼ | $-325.83K ▲ | $-115.68K ▼ | $-6.1M ▼ | $-5.66M ▼ |
| Q4-2024 | $-10.93M ▼ | $-2M ▼ | $-14.34M ▼ | $56.14M ▲ | $39.8M ▲ | $-2M ▼ |
| Q3-2024 | $-1.3M | $-1.07M | $985.73K | $-16.53K | $-99.85K | $-1.07M |
CEO
Chandler D. Robinson MBA, MSc
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-13 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
BTIG
Buy
Raymond James
Outperform
Oppenheimer
Outperform
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:1.29M
Value:$87.66M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:659.2K
Value:$44.88M
RA CAPITAL MANAGEMENT, L.P.
Shares:511.21K
Value:$34.81M
Summary
Showing Top 3 of 58